Zimbabwe has earned widespread international praise for its achievements in the fight against HIV, with the latest UNAIDS Global AIDS Update 2025 placing the ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 ...

Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

Just yesterday, UNICEF released its 2025 Global HIV Estimates — and the numbers are a sobering call to action. While the world has made undeniable progress in reducing HIV infections among children, ...

The World Health Organization has recommended the use of injectable lenacapavir (LEN) twice a year as an additional ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

The World Health Organization (WHO) on Monday recommended countries to use the twice-a-year lenacapavir injection as an add ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...